BRAFTOVI + MEKTOVI
BRAFTOVI (encorafenib) plus MEKTOVI (binimetinib), both from Pfizer, is a targeted regimen for tumors with specific BRAF pathway alterations.
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and BRAFTOVI + MEKTOVI. Select a testing pathway to see the eligible companion diagnostic tests.
Approvals where BRAFTOVI + MEKTOVI is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Melanoma Solid Tumor · Melanoma | BRAF
| View testing pathway → | |
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung | BRAF
| View testing pathway → |
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for BRAFTOVI + MEKTOVI.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering BRAFTOVI + MEKTOVI for eligible patients.